News
nContact to Initiate CONVERGE IDE Clinical Trial

MORRISVILLE, N.C., May 9, 2013 (GLOBE NEWSWIRE) — nContact, Inc. today announced that it has received conditional approval for an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in the CONVERGE trial, a multicenter, prospective, randomized study evaluating patients with symptomatic persistent atrial fibrillation (AF). AF is the most common cardiac arrhythmia, a condition that disrupts the ability of the atria (upper chambers of the heart) to beat regularly and pump blood efficiently…
Read the full story here.